Multiple sclerosis remains one of the most challenging neurological diseases, affecting more than 2.8 million people worldwide and approximately 1 million in the USA, with many patients experiencing worsening disability despite available treatments. Current therapies often focus on reducing inflammation and relapse frequency but may not adequately address the underlying neurodegeneration and myelin damage that drive long-term disease progression. Against this backdrop, Quantum BioPharma (NASDAQ: QNTM) is advancing Lucid-MS, a patented therapeutic candidate designed to target demyelination and provide neuroprotection in multiple sclerosis.
Quantum BioPharma announced the completion of phase 1 clinical studies involving healthy volunteers, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated. This milestone follows the company's submission of an Investigational New Drug application to the U.S. Food and Drug Administration in April 2026 for LUCID-MS. The company’s LUCID-MS program is built around the unmet need for MS therapies capable of directly protecting or restoring myelin integrity that affects the loss of mobility or control of a person’s body.
Multiple sclerosis is a chronic autoimmune and neurodegenerative disease in which the immune system attacks myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord. As myelin deteriorates, communication between nerves becomes disrupted, leading to symptoms that can include loss of mobility and function. The LUCID-MS candidate aims to address this core pathology, offering a potential shift from symptom management to disease modification.
The news is significant for the MS community and the biotech industry. If LUCID-MS proves effective in later-stage trials, it could provide a therapy that not only slows progression but also potentially repairs damage, a capability lacking in current treatments. This would impact patients' quality of life and reduce the burden on healthcare systems. For investors, the completion of Phase 1 and the IND submission signal progress toward a novel therapeutic approach, though forward-looking statements caution that actual results may differ materially due to risks and uncertainties.
For more information, the latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. As with all forward-looking statements, undue reliance should not be placed on them, and the company undertakes no duty to update this information unless required by law.
